The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...

Goldman Sachs rates Vaxcyte a buy with $135 price target, highlighting vaccine platform and pneumonia candidate. Read more ...

The National Pharmaceutical Pricing Authority (NPPA) has sought expertise from the Indian Patent Office to assist in making ...

Pneumococcal conjugate vaccines (PCVs) are known to provide protection against vaccine serotype pneumococcal pneumonia; uncertainty exists regarding the optimum PCV dosing schedule. Methods ...

Since pneumococcal conjugate vaccines (PCVs) promise better immune responses than PPV, vaccinating at-risk adults with PCV (with or without boosters with PPV) has been proposed; however ...

An ageing population, rising antimicrobial resistance, and the ongoing threat of infectious and chronic diseases are placing ...

The authors call for stronger vaccination systems, interventions, and catch-up campaigns in underserved populations.

It is important to consolidate data on PCV10 and PCV13 impact on invasive pneumococcal disease (IPD) in all ages to determine persistent vaccine-type serotypes and the main replacement non-vaccine ...

Fintel reports that on December 20, 2024, Goldman Sachs initiated coverage of Vaxcyte (NasdaqGS:PCVX) with a Buy ...

Prioritizing disease prevention naturally requires implementing effective immunization campaigns while also fostering an ...

Stifel Financial Corp boosted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 16.7% during ...